GEVA : Analysis & Opinions

  1. Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - ...

    January 28, 2015
    Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB ...
Trading Center